Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

54.81 +0.53 (+0.98%)

Streaming Delayed Price Updated: 11:59 AM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

86 87 Next >

3 Stocks With Mouthwatering Dividends You Can Buy Right Now ↗

June 08, 2025

Via The Motley Fool

Topics Intellectual Property

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A High-Yield Dividend Stock Worth Considering ↗

June 06, 2025

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.18% dividend yield with strong profitability and reasonable valuation, making it a compelling choice for dividend investors.

Via Chartmill

Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis ↗

June 05, 2025

Via The Motley Fool

Topics Intellectual Property Retirement

1 Cash-Producing Stock to Own for Decades and 2 to Think Twice About

June 05, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point ↗

June 04, 2025

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

Via Benzinga

Why BioNTech Stock Soared Today ↗

June 02, 2025

Bristol Myers Squibb just agreed to shower BioNTech with cash.

Via The Motley Fool

Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug ↗

June 02, 2025

BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion.

Via Benzinga

Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug ↗

June 02, 2025

BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028.

Via Stocktwits

Topics Government

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

June 02, 2025

From Bristol Myers Squibb

Via Business Wire

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A Potentially Undervalued Dividend Stock ↗

May 31, 2025

BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high dividend yield, strong profitability, and an undervalued stock price, making it a candidate for value investors.

Via Chartmill

1 S&P 500 Stock for Long-Term Investors and 2 to Brush Off

May 29, 2025

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Via StockStory

Topics Stocks

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

May 28, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

May 22, 2025

From Bristol Myers Squibb

Via Business Wire

1 Safe-and-Steady Stock to Own for Decades and 2 to Think Twice About

May 22, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference

May 21, 2025

From Bristol Myers Squibb

Via Business Wire

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

May 21, 2025

Via The Motley Fool

Topics Economy Law Enforcement

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 20, 2025

Via Benzinga

Options Corner: Political Turmoil Sets Up A Contrarian Call Spread For Bristol-Myers Squibb ↗

May 16, 2025

Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock.

Via Benzinga

Topics Government

3 Stocks That Will Profit From Trump's Drug Price Cut ↗

May 16, 2025

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

Via Benzinga

Topics Government

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%

May 16, 2025

From Bristol Myers Squibb

Via Business Wire

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering ↗

May 16, 2025

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers a high 5.29% dividend yield with strong growth and profitability, making it a solid pick for income investors.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

May 15, 2025

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.

Via Chartmill

What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks ↗

May 15, 2025

Via The Motley Fool

Topics Economy Government

Stay informed with the top movers within the S&P500 index on Wednesday. ↗

May 14, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.

Via Chartmill

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗

May 14, 2025

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Via Benzinga

CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up ↗

May 14, 2025

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

Via Benzinga

Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit ↗

May 13, 2025

Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial.

Via Benzinga

Topics Lawsuit

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News ↗

May 13, 2025

It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected.

Via Investor's Business Daily

Topics Economy Government

Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN) ↗

May 13, 2025

Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative.

Via Chartmill

Topics Government World Trade

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

86 87 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.